Arno Muller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arno Muller has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anita Kotwani
Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110007, India
2 shared publications - Benedikt Huttner
Antimicrobial Resistance Department, World Health Organization, 20, Avenue Appia, 1211 Geneva, Switzerland
2 shared publications - Elizabeth Ellen Roughead
Clinical and Health Sciences, University of South Australia, Adelaide 5000, Australia
2 shared publications - Martina Escher
Antimicrobial Resistance Department, World Health Organization, 20, Avenue Appia, 1211 Geneva, Switzerland
2 shared publications - Verica Ivanovska
Antimicrobial Resistance Department, World Health Organization, 20, Avenue Appia, 1211 Geneva, Switzerland
2 shared publications - Adi Al-Nuseirat
Access to Medicines and Health Technologies Unit, World Health Organization Office for the Eastern Mediterranean Region, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 16 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1161
Overview of Methods for Assessing Antimicrobial Use in Outpatient Settings in High-Income Countries: A Narrative Review
Background/Objectives: Over 80–90% of antibiotics are used in outpatient settings, where interactions among diverse prescribers, dispensers, and patients create complex usage patterns. The study examines how outpatient antimicrobial use is monitored in high-income countries (HICs), focusing on data sources and their relevance for stewardship and surveillance. Methods: This narrative review searched MEDLINE and Embase for English-language studies reporting outpatient antimicrobial use in HICs (from inception to 2023), supplemented by reference screening, targeted Google web searches, and expert input. Studies were categorized by data collection method, study period, and WHO Region. Key characteristics such as patient group, disease focus, country, dataset, and reported outcome measures were also extracted and tabulated. Results: We identified 287 studies, of which 79 met inclusion criteria. Most (n = 76) were conducted after 2000 and spanned all four WHO regions with HICs. Of the 73 studies using surveillance databases, six types were identified: dispensing (n = 13), health insurance (n = 24), GP prescribing (n = 17), commercial (n = 9), procurement (n = 3), and multinational networks (n = 7). Six studies used surveys: general point prevalence (n = 1), indication-specific audits (n = 3), patient exit interviews (n = 1), and community surveys (n = 1). Common outcome measures included DID, Days of Therapy, and patterns of antimicrobial use by season, age, sex, indication, and prescriber. Of the 48 studies published after 2018, nine reported using AWaRe metrics. Conclusions: Surveillance databases were the main method for tracking outpatient antimicrobial use in HICs; surveys were less common. Antibiotic use has increasingly been reported by AWaRe category, especially in prescribing and insurance studies. Further indicators and tech-driven tools are needed to support stewardship.
- 16 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1161
Open AccessOverview of Methods for Assessing Antimicrobial Use in Outpatient Settings in High-Income Countries: A Narrative Review
Background/Objectives: Over 80–90% of antibiotics are used in outpatient settings, where interactions among diverse prescribers, dispensers, and patients create complex usage patterns. The study examines how outpatient antimicrobial use is monitored in high-income countries (HICs), focusing on data sources and their relevance for stewardship and surveillance. Methods: This narrative review searched MEDLINE and Embase for English-language studies reporting outpatient antimicrobial use in HICs (from inception to 2023), supplemented by reference screening, targeted Google web searches, and expert input. Studies were categorized by data collection method, study period, and WHO Region. Key characteristics such as patient group, disease focus, country, dataset, and reported outcome measures were also extracted and tabulated. Results: We identified 287 studies, of which 79 met inclusion criteria. Most (n = 76) were conducted after 2000 and spanned all four WHO regions with HICs. Of the 73 studies using surveillance databases, six types were identified: dispensing (n = 13), health insurance (n = 24), GP prescribing (n = 17), commercial (n = 9), procurement (n = 3), and multinational networks (n = 7). Six studies used surveys: general point prevalence (n = 1), indication-specific audits (n = 3), patient exit interviews (n = 1), and community surveys (n = 1). Common outcome measures included DID, Days of Therapy, and patterns of antimicrobial use by season, age, sex, indication, and prescriber. Of the 48 studies published after 2018, nine reported using AWaRe metrics. Conclusions: Surveillance databases were the main method for tracking outpatient antimicrobial use in HICs; surveys were less common. Antibiotic use has increasingly been reported by AWaRe category, especially in prescribing and insurance studies. Further indicators and tech-driven tools are needed to support stewardship.
- Open Access
- 15 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1159
Inventory of Survey Instruments for Monitoring Antimicrobial Use in Primary Care Settings in Low- and Middle-Income Countries: A Narrative Review
Background: Over 80–90% of antimicrobial use occurs in primary health care, underscoring the need for specific data from this sector to inform practices and interventions to improve antimicrobial use. This study aimed to identify a wide range of research instruments in primary health care and qualitatively describe their structure, scope, and content. Methods: For the narrative review, we reviewed Medline (inception–November 2023) and agency/network websites to identify surveys on antimicrobial use prevalence in LMIC primary care. We applied no language restrictions and extracted survey instruments from publications or requested them from authors when unavailable. Results: We identified 450 studies and extracted 42 survey instruments issued between 1993 and 2023, all but one post-2000. These covered both multi-country (16.7%) and country-specific implementations across all WHO regions. Sampling units included households/consumers (24/42, 57.2%), health professionals (14/42, 33.3%), drug sellers (3/42, 7.1%), and bulk sales data (1/42, 2.4%). Surveys typically captured antimicrobial type, prescription status, and reason for use; AWaRe classification was mentioned only once. We found 13 stand-alone protocols on antimicrobial use and 4 on general medicine use. Conclusions: We identified diverse tools for measuring antimicrobial use in LMICs, though many lacked protocols or analytic support. Surveys often focused solely on antibiotics, used paper-based methods, and rarely referenced the AWaRe classification. Future efforts should broaden the scope beyond antibiotics, leverage digital data systems, include implementation protocols and analytic tools, report standardized indicators, and adopt AWaRe-related variables as a core criterion to strengthen AMU monitoring in PHC.
- 15 November 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (11) , 1159
Open AccessInventory of Survey Instruments for Monitoring Antimicrobial Use in Primary Care Settings in Low- and Middle-Income Countries: A Narrative Review
Background: Over 80–90% of antimicrobial use occurs in primary health care, underscoring the need for specific data from this sector to inform practices and interventions to improve antimicrobial use. This study aimed to identify a wide range of research instruments in primary health care and qualitatively describe their structure, scope, and content. Methods: For the narrative review, we reviewed Medline (inception–November 2023) and agency/network websites to identify surveys on antimicrobial use prevalence in LMIC primary care. We applied no language restrictions and extracted survey instruments from publications or requested them from authors when unavailable. Results: We identified 450 studies and extracted 42 survey instruments issued between 1993 and 2023, all but one post-2000. These covered both multi-country (16.7%) and country-specific implementations across all WHO regions. Sampling units included households/consumers (24/42, 57.2%), health professionals (14/42, 33.3%), drug sellers (3/42, 7.1%), and bulk sales data (1/42, 2.4%). Surveys typically captured antimicrobial type, prescription status, and reason for use; AWaRe classification was mentioned only once. We found 13 stand-alone protocols on antimicrobial use and 4 on general medicine use. Conclusions: We identified diverse tools for measuring antimicrobial use in LMICs, though many lacked protocols or analytic support. Surveys often focused solely on antibiotics, used paper-based methods, and rarely referenced the AWaRe classification. Future efforts should broaden the scope beyond antibiotics, leverage digital data systems, include implementation protocols and analytic tools, report standardized indicators, and adopt AWaRe-related variables as a core criterion to strengthen AMU monitoring in PHC.
- Open Access
- 9 June 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (6) , 690
An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
Coronavirus disease 2019 (COVID-19) has overlapping clinical characteristics with bacterial respiratory tract infection, leading to the prescription of potentially unnecessary antibiotics. This study aimed at measuring changes and patterns of national antimicrobial use for one year preceding and one year during the COVID-19 pandemic. Annual national antimicrobial consumption for 2019 and 2020 was obtained from the Jordan Food and Drug Administration (JFDA) following the WHO surveillance methods. The WHO Access, Watch, and Reserve (AWaRe) classification was used. Total antibiotic consumption in 2020 (26.8 DDD per 1000 inhabitants per day) decreased by 5.5% compared to 2019 (28.4 DDD per 1000 inhabitants per day). There was an increase in the use of several antibiotics during 2020 compared with 2019 (third generation cephalosporins (19%), carbapenems (52%), macrolides (57%), and lincosamides (106%)). In 2020, there was a marked reduction in amoxicillin use (−53%), while the use of azithromycin increased by 74%. National antimicrobial consumption of the Access group decreased by 18% from 2019 to 2020 (59.1% vs. 48.1% of total consumption). The use of the Watch group increased in 2020 by 26%. The study highlighted an increase in the use of certain antibiotics during the pandemic period that are known to be associated with increasing resistance. Efforts to enhance national antimicrobial stewardship are needed to ensure rational use of antimicrobials.
- 9 June 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (6) , 690
Open AccessAn Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
Coronavirus disease 2019 (COVID-19) has overlapping clinical characteristics with bacterial respiratory tract infection, leading to the prescription of potentially unnecessary antibiotics. This study aimed at measuring changes and patterns of national antimicrobial use for one year preceding and one year during the COVID-19 pandemic. Annual national antimicrobial consumption for 2019 and 2020 was obtained from the Jordan Food and Drug Administration (JFDA) following the WHO surveillance methods. The WHO Access, Watch, and Reserve (AWaRe) classification was used. Total antibiotic consumption in 2020 (26.8 DDD per 1000 inhabitants per day) decreased by 5.5% compared to 2019 (28.4 DDD per 1000 inhabitants per day). There was an increase in the use of several antibiotics during 2020 compared with 2019 (third generation cephalosporins (19%), carbapenems (52%), macrolides (57%), and lincosamides (106%)). In 2020, there was a marked reduction in amoxicillin use (−53%), while the use of azithromycin increased by 74%. National antimicrobial consumption of the Access group decreased by 18% from 2019 to 2020 (59.1% vs. 48.1% of total consumption). The use of the Watch group increased in 2020 by 26%. The study highlighted an increase in the use of certain antibiotics during the pandemic period that are known to be associated with increasing resistance. Efforts to enhance national antimicrobial stewardship are needed to ensure rational use of antimicrobials.